Want to see QDEL full AI Analyst Report?
QDEL Stock Chart & Stats
$15.05
$0.78(4.86%)
At close: 4:00 PM EDT
$15.05
$0.78(4.86%)
Day’s Range― - ―
52-Week Range$9.92 - $35.58
Previous Close$16.9
Volume1.06M
Average Volume (3M)1.88M
Market Cap
$875.02M
Enterprise Value$3.89B
Total Cash (Recent Filing)$123.40M
Total Debt (Recent Filing)$3.08B
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 03, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.44
Shares Outstanding68,575,424
10 Day Avg. Volume2,606,591
30 Day Avg. Volume1,882,599
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.03
Price to Sales (P/S)0.73
P/FCF Ratio-23.93
Enterprise Value/Market Cap4.45
Enterprise Value/Revenue1.46
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda-10.19
Forecast
1Y Price Target
$12.00Price Target Upside-20.27% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)0.77
Revenue Forecast (FY)$2.54B
Bulls Say, Bears Say
Bulls Say
Ex-China Franchise GrowthGrowth across laboratories, immunohematology, and point-of-care testing outside China indicates resilient demand across multiple franchises. Because roughly 90% of revenue comes from outside China, this geographic and portfolio breadth can support recurring consumables and instrument utilization over coming quarters.
EBITDA And Margin ExpansionStrong adjusted EBITDA growth and wider margins show that operating discipline is improving earnings conversion even in a seasonally weak quarter. If sustained, productivity initiatives and controlled operating-expense growth could strengthen profitability and provide greater capacity to invest or reduce leverage.
Lex And Neulixa CommercializationThe Lex acquisition adds a commercialization opportunity beyond the existing portfolio, with management reporting progress toward scale-up, launch readiness, and customer adoption. Successful placements and utilization could broaden the respiratory offering and create additional recurring testing demand in later periods.
Bears Say
China Pricing UncertaintyProposed pricing changes are affecting customer purchasing behavior and have already produced a sharp China revenue decline. The broadened product scope and expanded pilot provinces make the uncertainty more persistent, creating a durable regional headwind for demand, mix, and revenue visibility.
Negative Cash GenerationCurrent cash consumption means the business is not funding operations and investment internally, increasing reliance on available liquidity and financing. Withdrawal of free-cash-flow guidance also signals that working-capital effects and demand uncertainty may continue to make cash conversion difficult over the next several quarters.
Elevated Financing ConstraintsThe amended credit agreement provides covenant relief but also highlights continued financing pressure through staged leverage and interest-coverage requirements. Restrictions on asset sales, additional debt, and distributions can limit management flexibility and make deleveraging and capital allocation more important priorities.
QuidelOrtho News
QDEL FAQ
What was QuidelOrtho’s price range in the past 12 months?
QuidelOrtho lowest stock price was $9.92 and its highest was $35.58 in the past 12 months.
What is QuidelOrtho’s market cap?
QuidelOrtho’s market cap is $875.02M.
When is QuidelOrtho’s upcoming earnings report date?
QuidelOrtho’s upcoming earnings report date is Nov 03, 2026 which is in 13 days.
How were QuidelOrtho’s earnings last quarter?
QuidelOrtho released its earnings results on Aug 06, 2026. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of -$0.049 by $0.179.
Is QuidelOrtho overvalued?
According to Wall Street analysts QuidelOrtho’s price is currently Overvalued.
Does QuidelOrtho pay dividends?
QuidelOrtho does not currently pay dividends.
What is QuidelOrtho’s EPS estimate?
QuidelOrtho’s EPS estimate is 0.2.
How many shares outstanding does QuidelOrtho have?
QuidelOrtho has 68,575,424 shares outstanding.
What happened to QuidelOrtho’s price movement after its last earnings report?
QuidelOrtho reported an EPS of $0.13 in its last earnings report, beating expectations of -$0.049. Following the earnings report the stock price went down -24.724%.
Which hedge fund is a major shareholder of QuidelOrtho?
Currently, no hedge funds are holding shares in QDEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.00 (-20.27% Downside)
$12.00 (-20.27% Downside)
Blogger Sentiment
Neutral
QDEL Sentiment 67%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 439.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.63%
12-Months-Change
Fundamentals
Return on Equity
-55.30%
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
QuidelOrtho
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QDEL Company Deck
QDEL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: solid underlying operational performance outside China (mid-single-digit growth ex-China, strong regional results, 21% YoY adjusted EBITDA growth, and margin expansion) and tangible progress on the Lex/Neulixa commercialization. Offsetting these positives were significant near-term headwinds — a 23% revenue decline in China driven by IVD pricing uncertainty, a softer respiratory season, negative operating and free cash flow in the quarter, withdrawal of free-cash-flow guidance, and elevated leverage (4.3x). Management emphasized disciplined cost actions, cash-conversion priorities, and mitigation plans, but the combination of China uncertainty and weak respiratory demand creates meaningful short-term risk even as core franchises remain resilient.View all QDEL earnings summariesQDEL Stock 12 Month Forecast
Average Price Target
$12.00
▼(-20.27% Downside)
Technical Analysis
Ownership Overview
0.91% Insiders
40.99% Mutual Funds
0.10% Other Institutional Investors
22.81% Public Companies and
Individual Investors